anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1433828 Cycloheptaamylose inclusion complexes H TROMMSDORFF 28 Nov 1973 [11 Dec 1972] 55279/73 Heading C2S [Also in Division A5] A molecular inclusion compound comprises a silver alkanolammine complex and cycloheptaamylose having 1 to 3 gram atoms silver per 10 mol cycloheptaamylose. The compound is presumed to have the formula where x is from 0À10 to 0À30, R is an alkylene radical having 2 to 5 carbon atoms and Y is the anion of a silver salt which is soluble in an alkanolamine. The alkanolamine is for example monoethanolamine, #-amino-n-propanol, #- hydroxy-isopropylamine, monobutanolamine or monopentanolamine; the silver salt is for example the nitrate, chloride, acetate, oxalate or tartrate. The compound may be prepared by (a) dissolving cycloheptaamylose in an alkanolamine, dissolving the silver salt in the resultant solution or (b) reacting salt and alkanolamine to form silver alkanolamine complex, and then adding the cycloheptaamylose; the inclusion compound is then crystallized out. Crystallization may be brought about by cooling or adding a precipitant, e.g. ethanol or propanol. The inclusion compound has pharmaceutical use and may be formulated into compositions with solid or liquid diluents or carriers.
ABI-007-COLO-001 is a Phase 2, single arm, open label, multicenter study to evaluate the efficacy and safety of Abraxane (nab-paclitaxel) given on days 1, 8 and 15 of a 28 day cycle in subjects with previously treated metastatic colorectal cancer. Subjects will be enrolled into cohorts by RAS mutation status (wildtype or mutated). Stage 1 in a given cohort will enroll 15 subjects in the Intention to Treat population and if more than 8 subjects have Progression Free Survival at the 8 week assessment, then Stage 2 will open in the respective cohort. Stage 2 will enroll an additional 28 subjects for a total of 43 subjects in each cohort. The study will be positive if more than 26 subjects with Progression Free Survival at the 8 week assessment are observed in 43 subjects per cohort. Interim analysis after Stage 1 did not meet protocol defined criteria to proceed to Stage 2. Patients currently enrolled will be followed for Progression Free Survival and until 28 days after last dose, secondary endpoints including overall survival will not be followed
<P>PROBLEM TO BE SOLVED: To provide a means for ameliorating morphologic change of a keratinous layer accompanied with cornification sthenia as observed at an elbow portion and a heel portion without feeling of stimulation.  <P>SOLUTION: As the means, (1) urea and (2) trehalose are added to an emulsion type cosmetic material. The mass ratio of urea and trehalose is preferably 1:2-50:1. The content of urea is preferably 0.05-20 mass%. The sum total of fatty acid triglyceride and a fatty acid ester with a monohydric alcohol is preferably ≤10 mass% based on the total amount of the cosmetic material. The cosmetic material is preferably applied to soften a keratinous sclerotized spot of the elbow portion or the heel portion.  <P>COPYRIGHT: (C)2008,JPO&INPIT
The recommended treatment regimen, duration, and recommended dosage for SOVALDI combination therapy is provided in Table 2 and Table 3. Table 4 provides the weight-based dosage of ribavirin when used in combination with SOVALDI for pediatric patients. For patients with HCV/HIV-1 coinfection, follow the dosage recommendations in Table 3 and Table 4. Refer to Drug Interactions (7) for dosage recommendations for concomitant HIV-1 antiviral drugs. In pediatric patients with hepatocellular carcinoma awaiting liver transplantation, administer SOVALDI in combination with ribavirin for up to 48 weeks or until the time of liver transplantation, whichever occurs first, to prevent post-transplant HCV reinfection [see Use in Specific Populations (8.8)].

The recommended dosage of SOVALDI in pediatric patients 3 years and older with genotype 2 or 3 HCV using SOVALDI tablets or oral pellets (with or without food) is based on weight (Table 3), and is to be taken orally once daily in combination with ribavirin [see Dosage and Administration (2.4), Use in Specific Populations (8.4), Clinical Pharmacology (12.3), and Clinical Studies (14.5)]. SOVALDI pellets can be taken by pediatric patients who cannot swallow the tablet formulation [see Dosage and Administration (2.4)].
Participants randomized to the breakfast group will be instructed to consume breakfast before 10:00 a.m. every day, and will be asked to not eat again until after 11:00 a.m. Participants will be counseled on what a healthy breakfast is using an instruction handout. No specific restrictions will be given on types of foods that can be consumed for the breakfast meal. They will be instructed to keep track of their breakfast consumption (yes/no) using a calendar diary that will be provided to them. Participants will also be provided with a free USDA nutrition pamphlet describing general good nutrition habits. The clinician will go through both documents with participants in detail by reading them aloud and answering any questions, and it will be recommended that they incorporate the recommendations into their daily life as much as they can.
Addictive disorders are a public health priority. The management of addictive disorders aims to reduce addictive behaviour or abstinence, implying that the patient can overcome the urge to engage in this behaviour, a symptom called craving.

Craving, as a major motivational substrate for addictive behaviour, is a preferred therapeutic target for the management of addictive disorders. However, to date, there are no fully effective drugs or psychological interventions. Smartphone applications seem to have an interest in this context, with many advantages: accessibility, anonymity, ease of access and low cost. Sainte Anne's Hospital Moreau de Tour facility (Paris, France) was one of the pioneering centres in the management of addictive disorders. The nursing team has developed expertise in this field. Patients report difficulties to nurses about managing their craving on their own, and ask for more frequent interviews or even daily support. During practice analysis meetings, caregivers sought innovative solutions to optimize this care. Our team has designed the PHOENIX application, which allows us to support patients in real time who wish to reduce or stop their addictive behaviours. Used between two consultations, it targets craving, without being specific to a product or addictive behaviour. When the patient has a craving, PHOENIX identifies the situation and proposes the most appropriate strategy to avoid using. Strategies are personalized and self-adaptive. The application allows caregivers to monitor patients' progress and progress.

Hypothesis of this study: The PHOENIX application used as a complement to nursing care will allow a better management of craving and a decrease in relapses compared to usual care (usual care: multidisciplinary care including nursing care).
This group will receive placebo oral cherry elixir prior to going to the operating room and placebo Ofirmev® after securing intravenous access in the operating room with redosing every six hours. They will receive local anesthetic (Lidocaine 0.5% with Epinephrine) infiltration by the surgeon prior to incision as well as at the completion of surgery with Bupivicaine 0.25% with Epinephrine. Postoperatively they will receive only Morphine prn for pain control.
PROBLEM TO BE SOLVED: To obtain a massage cream which can remove positive static electricity and activate the cells constituting human body and humor such as blood by using silicon oxide in the cream. SOLUTION: This massage cream contain 0.3-85wt.% of silicon oxide which is SiO2 and composed of sphere particles with a particle size of <=3μm. Anions are ejected from the silicon oxide to neutralize the positive static electricity on the body surface or inside the body to convert to minus charge. In addition, the released anions activate the oxygen in the peripheral air. These activated oxygen or anions directly activate cells and body fluid such as blood. The silicon oxide is desirably ionized negatively and larger effect is attained as the degree of anionization becomes higher. Coupled with the pointillage, the ionization effect enables the recovery to healthy body.
NEW MATERIAL:A compound shown by the formula I [R is H, alkyl, alkoxyalkyl, oxiranylalkyl, group shown by the formula II or III (R1 and R2 are H, 1-4C alkyl, aryl, aralkyl, or R1 and R2 are linked to neighboring nitrogen to form heterocycic ring; n is 2, or 3)] and its nontoxic salt. EXAMPLE:A compound shown by the formula IV. USE:A cerebral function improver (cerebrovascular vasodilating action and cere bral activating action) having high pharmaceutical action and improved durabil ity. PREPARATION:An eburnamoninethione shown by the formula V is reacted with hydroxylamine in a solvent such as ethanol, etc., in the presence of an alkali metallic carvonate (e.g., excess amount of potassium carbonate, etc.) preferably under condition of the boiling point of the solvent (R is H). Then, the prepared eburamonine oxide is reacted with an alkali metal hydride in an anhydrous organic solvent such as DMF, etc., and further reacted with a compound shown by the formula R<0>X (R<0> is alkyl, alkoxyalkyl, oxiranylalkyl, or group shown by the formula II; X is halogen) preferably at 0-60 deg.C.
The present invention relates to a xueguiling analgesic medicine which is prepared by that dragon blood, angelica, tuckahoe, cortex moutan, lotus seed, safflower, rhubarb, liquoric root, costustoot and rhizoma corydalis are used as main ingredients. One or composite ingredients of a plurality of Chinese magnoliavine fruit, ophiopogonis radix, catechu and bitter orange are used as auxiliary materials. The medicine of the present invention realizes the analgesic effects by activating blood circulation, dissipating blood stases, dredging the meridian passage, regulating cardiac exercise and regulating and controlling from the central pivot to the two surrounding directions. The medicine of the present invention has the functions of neuroendocrine mechanisms of regulating and resisting pains and regulating immune systems. When the medicine of the present invention is taken for a long time, no addiction or dependency is formed, and no somnolence or vertigo exists. Particularly, water-sodium metabolism can not be influenced; the medicine of the present invention has the advantages of no side effect and long duration time of medicine effect.
Diabetic kidney disease (DKD) is the leading cause of end-stage kidney disease in the United States and worldwide. Proteinuria is a major marker of the severity of injury. Dipeptidyl peptidase-4 inhibitor (DPP-4I) increases incretin-related insulin production and is, therefore, used to treat diabetes. We investigated whether DPP4I could have direct effect on kidney independent of its hypoglycemic activity. We, therefore, tested the effects of DPP4I with or without angiotensin-converting enzyme inhibitor (ACEI) on the progression of diabetic nephropathy and albuminuria in a murine model of DKD. eNOS-/-db/db mice were randomized to the following groups at age 10 weeks and treated until sacrifice: baseline (sacrificed at week 10), untreated control, ACEI, DPP4I, and combination of DPP4I and ACEI (Combo, sacrificed at week 18). Systemic parameters and urine albumin-creatinine ratio were assessed at baseline, weeks 14, and 18. Kidney morphology, glomerular filtration rate (GFR), WT-1, a marker for differentiated podocytes, podoplanin, a marker of foot process integrity, glomerular collagen IV, and alpha-smooth muscle actin were assessed at the end of the study. All mice had hyperglycemia and proteinuria at study entry at week 10. Untreated control mice had increased albuminuria, progression of glomerular injury, and reduced GFR at week 18 compared with baseline. DPP4I alone reduced blood glucose and kidney DPP-4 activity but failed to protect against kidney injury compared with untreated control. ACEI alone and combination groups showed significantly reduced albuminuria and glomerular injury, and maintained GFR and WT-1+ cells. Only the combination group had significantly less glomerular collagen IV deposition and more podoplanin preservation than the untreated control. DPP-4I alone does not decrease the progression of kidney injury in the eNOS-/-db/db mouse model, suggesting that targeting only hyperglycemia is not an optimal treatment strategy for DKD. Combined DPP-4I with ACEI added more benefit to reducing the glomerular matrix.
A system and method for identifying patient records within a pharmacy benefit plan that are candidates for correction are provided. The system and method identify candidate patient records that satisfy undermatch criteria. Last change dates are determined for the candidate records that satisfy the undermatch criteria. The last change dates indicate when demographic information within the candidate records last changed. Last usage dates are determined for a lesser-utilized subset of the patient identifiers in the set. A correction subset of the candidate records is prioritized for correction. The candidate records are prioritized for correction being the candidate records that satisfy the undermatch criteria, that were not corrected since the last change date, and that have the patient identifiers within the lesser-utilized subset. A portion of the correction subset is supplied to a correction engine based on prioritization of the correction subset and a capacity constraint of the correction engine.
Randomized, controlled, modified dose-escalation design. Patients receive standard monitoring for anesthesia and postoperative care. Surgical and anesthesia (except for opioid use) care are not altered for study purposes. All patients are induced by propofol and muscle relaxants. In the first cohort (n=30 evaluable), subjects are randomized 1:2 to either control (standard intraop opioid at anesthesiologists' discretion) or methadone HCl (0.4 mg/kg ideal body weight, IBW). In the second cohort (n=30 evaluable), subjects are randomized 1:2 to either control (standard intraop opioid) or methadone HCl (0.3 mg/kg ideal body weight, IBW). Subjects in the study groups will receive methadone (IV bolus, after induction of anesthesia) as their primary intraoperative opioid, rather than leaving the choice of intraoperative opioid to the anesthesiologist. Intraoperative breakthrough pain will be treated at the discretion of the anesthesiologist with fentanyl. In the control groups, intraoperative opioid administration will be left at the discretion of the anesthesia providers. Patient controlled analgesia as prescribed by the clinical team, using hydromorphone or morphine, will be used to treat postoperative pain relief.
We evaluated the use of autologus bone marrow stem cells transplantation in patients with critical limb ischaemia (CLI) not eligible for revascularization. Eighty consecutive patients candidate to amputation were enrolled in a single-centre retrospective study. The primary endpoint was defined as the amputation-free rate from stem cells transplantation. Secondary endpoints were the evaluation of transcutaneous oximetry and its predictive potential for probability of amputation and the evaluation of rest pain. Ankle brachial index, transcutaneous oxygen (TcpO2) and radiological imaging were performed at the enrolment and during the follow-up times. All patients were treated with auto transplant of bone marrow stem cells. Two patients died due to acute renal and acute respiratory failures. 19 patients were amputated from the thigh or leg. In total, 59 of 80 patients intended to thigh amputation saved the limb, preserving the plantar support. TcpO2 was found a predictive metric with an AUC equal to .763, and a threshold for a risk of amputation of 10% and 5% at the values ≤22.7 and ≤26.9 mmHg, respectively. Auto transplant of bone marrow stem cells seems to be a safe and an efficient option for CLI not eligible to revascularizzation.
ERAS (Enhanced recovery after surgery) strategy is extremely important for patients receiving esophagectomy including the preoperative preparation (smoking cessation, exercise prescription and nutrition prescription), intraoperative management, and postoperative analgesia and respiratory rehabilitation. However, despite the less invasive thoracoscopic esophagectomy and laparoscopic gastric tube reconstruction was developed, respiratory complications including acute lung injury (ALI) were observed up to 20% and associate with 50% of mortality. A new preventive anesthetic ERAS strategy including precise perioperative fluid management and preventive management after tracheal extubation should be developed.

Previous report indicated that none of the variables studied except fluid administration were shown as a risk factor for the development of respiratory complications on the multivariate analysis on esophageal surgery. However, there are rare prospective investigations of perioperative fluid administration strategy on postoperative complications after esophagectomy. Our group has studied on goal-directed fluid optimization and we found that the goal of optimization may differ for specific surgery. For esophagectomy, new anesthetic ERAS strategy should include precise preoptimized circulatory management and aggressive postoperative pulmonary care. Based on Frank-Starling law (stroke volume, SV, response to fluid therapy), a precise goal for perioperative goal-directed fluid therapy (GDFT) becomes possible in anesthetic practice. However, the effects of preoperative maximization of SV remain unknown. Following our study in last year, we planned to randomize 120 esophagectomy patients in the following 3 years into different GDFT groups (SV maximization and SV normalization groups). Postoperative THRIVE (Transnasal Humidified Rapid-Insufflation Ventilatory Exchange) therapy will be take place immediately after tracheal extubation. Blood samples will be obtained preoperatively to postoperative day 1 to measure lung injuries, kidney injuries as well as the inflammatory and oxidative markers. The clinical records will be collected (including extubation time, ICU stay, hospitalization days, 30-day mortality, 90-day mortality, readmission, postoperative cardiovascular, pulmonary, and renal complications, gastric tube related complications etc. ). The goals of this study are to testify the effectiveness on enhance recovery by new anesthetic ERAS strategy.
INTRODUCTION: Routine dipstick urinalysis is part of many dive medical assessment protocols. However, this has a significant chance of producing false-positive or false-negative results in asymptomatic and healthy individuals. Studies evaluating the value of urinalysis in dive medical assessments are limited.
METHODS: All results from urinalysis as part of dive medical assessments of divers, submarines, and hyperbaric personnel of the Royal Netherlands Navy from 2013 to 2023 were included in this study. Additionally, any information regarding additional testing, referral, or test results concerning the aforementioned was collected.
RESULTS: There were 5,899 assessments, resulting in 46 (0.8%) positive dipstick urinalysis results, predominantly microscopic haematuria. Females were significantly overrepresented, and revisions resulted in significantly more positive test results than initial assessments. Lastly, almost half of the cases were deemed fit to dive, while the other half were regarded as temporarily unfit. These cases required additional testing, and a urologist was consulted three times.
CONCLUSIONS: To our knowledge, this is the most extensive study evaluating urinalysis in dive medical assessments. In our military population, the incidence of positive test results is very low, and there have not been clinically relevant results over a period of 10 years. Therefore, routinely assessing urine in asymptomatic healthy military candidates is not cost-effective or efficacious. The authors advise taking a thorough history for fitness to dive assessments and only analysing urine when a clinical indication is present.
Cases of optic neuropathy and/or optic neuritis, usually resulting in visual impairment, have been reported in patients treated with amiodarone. In some cases, visual impairment has progressed to permanent blindness. Optic neuropathy and/or neuritis may occur at any time following initiation of therapy. A causal relationship to the drug has not been clearly established. If symptoms of visual impairment appear, such as changes in visual acuity and decreases in peripheral vision, prompt ophthalmic examination is recommended. Appearance of optic neuropathy and/or neuritis calls for re-evaluation of amiodarone therapy. The risks and complications of antiarrhythmic therapy with amiodarone must be weighed against its benefits in patients whose lives are threatened by cardiac arrhythmias. Regular ophthalmic examination, including funduscopy and slit-lamp examination, is recommended during administration of amiodarone (see ADVERSE REACTIONS).
BACKGROUND: Rhythm control is a cornerstone of atrial fibrillation (AF) management. Shorter time between diagnosis of AF and receipt of catheter ablation is associated with greater rates of therapy success. Previous work considered diagnosis-to-ablation time as a binary or categorical variable and did not consider the unique risk profile of patients after a referral for ablation was made.
OBJECTIVE: The purpose of this study was to comprehensively assess the impact of diagnosis-to-ablation and referral-to-ablation time on postprocedural outcomes at a population level.
METHODS: This observational cohort study included patients who received catheter ablation to treat AF in Ontario, Canada. Patient demographics, medical comorbidities, AF diagnosis date, ablation referral date, and ablation date were collected. The primary outcomes of interest included a composite of death and hospitalization/emergency department visit for AF, heart failure, or ischemic stroke. Multivariable Cox models assessed the impact of diagnosis-to-ablation and referral-to-ablation times on the primary outcome.
RESULTS: Our cohort included 7472 patients who received ablation for de novo AF between April 1, 2016, and March 31, 2022. Median [interquartile range] diagnosis-to-ablation time was 718 [399-1274] days and median referral-to-ablation time was 221 [117-363] days. Overall, 911 patients (12.2%) had the composite endpoint within 1 year of ablation. Increasing diagnosis-to-ablation time was associated with a greater incidence for the primary outcome (hazard ratio [HR]1.02; 95% confidence interval [CI] 1.01-1.02 per month). Increasing referral-to-ablation time did not impact the primary outcome (HR 1.00; 95% CI 0.98-1.01 per month).
CONCLUSION: Delays between AF diagnosis and ablation referral may contribute to adverse postprocedural outcomes and provide an opportunity for health system quality improvements.
PROBLEM TO BE SOLVED: To obtain a base composition for jelly agent, gel agent, ointment, cream, lotion, etc., to be used in cosmetics, pharmaceuticals, daily necessities and foods. SOLUTION: This base contains 10-90wt.% of a matrix agent composed of 0.05-2wt.% of gelan gum, a cation (e.g. calcium chloride) and water as the medium and having a gel strength of 100-2,500g/cm<2> in terms of curd value. The amount of the cation is 0.001-0.2mol concentration based on 0.2wt.% of gelan gum in the case of a bivalent cation, i.e., Ca<++> . The gelan gum is a product of Chelco Co. U.S.A. and gelatinized by dispersing in water, dissolving by heating and adding a cation-releasing salt or an H<+> -releasing acid to the solution. The matrix agent added to the base lowers the stringiness, stickiness and wet feeling and improves the penetrability without deteriorating the spreadability and the adhesivity of the base.